Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial-Reference-Cited by-同舟云学术

Triheptanoin versus trioctanoin for long-chain fatty acid oxidation disorders: a double blinded, randomized controlled trial

Published:2017-09-04 Issue:6 Volume:40 Page:831-843
ISSN:0141-8955
Container-title:Journal of Inherited Metabolic Disease
language:en
Short-container-title:J Inherit Metab Dis

Author:

Gillingham Melanie B.,Heitner Stephen B.,Martin Julie,Rose Sarah,Goldstein Amy,El-Gharbawy Areeg Hassan,Deward Stephanie,Lasarev Michael R.,Pollaro Jim,DeLany James P.,Burchill Luke J.,Goodpaster Bret,Shoemaker James,Matern Dietrich,Harding Cary O.,Vockley Jerry

Funder

U.S. Food and Drug Administration

Publisher

Wiley

Subject

Genetics(clinical),Genetics

Link

http://link.springer.com/article/10.1007/s10545-017-0085-8/fulltext.html

Reference38 articles.

1. Arnold GL, Van Hove J, Freedenberg D et al (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96:85–90

2. Behrend AM, Harding CO, Shoemaker JD et al (2012) Substrate oxidation and cardiac performance during exercise in disorders of long chain fatty acid oxidation. Mol Genet Metab 105:110–115

3. Bennett MJ, Rinaldo P, Wilcken B, Pass KA, Watson MS, Wanders RJ (2012) Newborn screening for metabolic disorders: how are we doing, and where are we going? Clin Chem 58:324–331